Login to Your Account

Orca Pharmaceuticals Ltd. and Astrazeneca plc are joining a growing list of alliances seeking to leverage retinoic acid-related orphan nuclear receptor gamma (RORγ) inhibitors to address a wide range of autoimmune diseases.

Ipsen SA plucked Canbex Therapeutics Ltd. in its prime, gaining an exclusive option to purchase the small University College London spin-off and forestall a potential competitor to its Dysport (abobotulinumtoxin A) franchise.

Canada's Valeant Pharmaceuticals International Inc. has moved to acquire gastrointestinal (GI) specialist Salix Pharmaceuticals Ltd. in an all-cash deal valued at about $10.1 billion, or $14.5 billion in enterprise value, a measure including Salix's debt and cash on hand.

More DEALS AND M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: